FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. ON/4-32326A
APPLICATION NO. 10/502,534
APPLICANT Heikki Joensuu
FILING DATE January 5, 2005
Group 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,521,184	5/28/96	Zimmermann			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	AM	EP 0 564 409	10/06/93	Europe (English equivalent is U.S. Patent No. 5,521,184)			☐	☐
	AN	*WO 99/03854	01/28/99	WIPO			☐	☐
	AO	WO 01/00214	01/04/01	WIPO			☐	☐
	AP	WO 01/64200 A2	09/07/01	WIPO			☐	☐
	AQ	*WO 02/080925	10/17/02	WIPO			☐	☐

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Buchdunger et al., "Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors", *J Pharmacol Exper Thera*, Vol. 295, No. 1, pp. 139-145 (2000).
	AS	Cwynarski et al., "STI571 Inhibits the Activation and Proliferation of Normal T Lymphocytes", *Blood*, Vol. 98, No. 11, Pt. 2, pp. 256b-257b (2001) – Abstract #4757 – DERWENT No. 2002-17328 DRUGU P.
	AT	Deininger, Goldman, Lydon and Melo, "The Tyrosine Kinase Inhibitor CGP 57148 Selectively Inhibits Hematopoietic Colony Formation by CML Progenitor Cells Over a 2-Log Dose Range", *Blood*, Vol. 88, No. 10, Suppl. 1, Pt. 1, p. 364a (1996) – Abstract #1444 – DERWENT No. 1997-07455 DRUGU P.

EXAMINER	/Leslie Royds/ (05/27/2008)	DATE CONSIDERED	

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LR/ (05/27/2008)

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. ON/4-32326A
APPLICATION NO. 10/502,534
APPLICANT Heikki Jo ensuu
FILING DATE January 5, 2005

Group 1614

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	CA	*WO 02/083075	10/24/02	WIPO			☐	☐
	CB	*WO 02/092091	11/21/02	WIPO			☐	☐
	CC	WO 02/45717	06/13/02	WIPO			☐	☐
	CD	*WO 03/002108	01/09/03	WIPO			☐	☐
	CE	WO 03/002109	01/09/03	WIPO			☐	☐
	CF						☐	☐
	CG						☐	☐
	CH						☐	☐
	CI						☐	☐
	CJ						☐	☐
	CK						☐	☐
	CL						☐	☐
	CM						☐	☐
	CN						☐	☐
	CO						☐	☐
	CP						☐	☐
	CQ						☐	☐
	CR						☐	☐
	CS						☐	☐
	CT						☐	☐
	CU						☐	☐
	CV						☐	☐
	CW						☐	☐
	CX						☐	☐
	CY						☐	☐
	CZ						☐	☐

EXAMINER /Leslie Royds/ (05/27/2008) **DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LR/ (05/27/2008)

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. ON/4-32326A
APPLICATION NO. 10/502,534
APPLICANT Heikki Joensuu
FILING DATE January 5, 2005
Group 1614

EXAMINER INITIAL		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)
	DA	Gilbert et al., "PDGF Signal Transduction Inhibition Ameliorates Mesangial Proliferative Glomerulonephritis", *J Am Soc Nephrol*, Vol. 11, p. 506A (2000) – Program #SU1131 (FC); Abstract #A2671 - BIOSIS No. 2002:252250 BIOSIS.
	DB	Gilbert et al., "PDGF Signal Transduction Inhibition Ameliorates Experimental Mesangial Proliferative Glomerulonephritis", *Kidney Int*, Vol. 59, No. 4, pp. 1324-1332 (2001).
	DC	Gordon et al., "The Tyrosine Kinase Inhibitor STI571 Preferentially Reduces the Capacity for Amplification of Granulocyte-Macrophage Progenitors (CFU-GM) from Patients With Chronic Myeloid Leukemia But Spares Normal CFU-GM", *Blood*, Vol. 94, No. 10, Suppl. 1, Pt. 1, p. 387a (1999) – Abstract #1718 – DERWENT No. 2000-15571 DRUGU P.
	DD	Marley et al., "The Tyrosine Kinase Inhibitor STI571, Like Interferon-α, Preferentially Reduces the Capacity for Amplification of Granulocyte-Macrophage Progenitors from Patients with Chronic Myeloid Leukemia", *Exp Hematol*, Vol. 28, No. 5, pp. 551-557 (2000).
	DE	Wang et al., "STI-571, a Selective Tyrosine Kinase Inhibitor, Significantly Enhances Antigen Presentation by Bone Marrow Derived APCs: Implications for Immunotherapy of Tumors-Derived from Antigen Presenting Cells", *Blood*, Vol. 98, No. 11, Pt. 1, p. 16a (2001) – Abstract #55, Poster Board #55-I – DERWENT No. 2002-138977 DRUGU P.
	DF	
	DG	
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER /Leslie Royds/ (05/27/2008) **DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LR/ (05/27/2008)